Imiquimod
- CAS No.
- 99011-02-6
- Chemical Name:
- Imiquimod
- Synonyms
- ALDARA;R-837;TMX101;S-26308;TMX 101;TMX-101;Zyclara;imiqimod;imiquimo;Miquimod
- CBNumber:
- CB2664655
- Molecular Formula:
- C14H16N4
- Molecular Weight:
- 240.3
- MOL File:
- 99011-02-6.mol
- Modify Date:
- 2024/7/5 11:27:04
| Melting point | 292-294°C |
|---|---|
| Boiling point | 456.7±48.0 °C(Predicted) |
| Density | 1.28±0.1 g/cm3(Predicted) |
| storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| solubility | DMSO: soluble |
| pka | 6.28±0.30(Predicted) |
| form | White solid |
| color | White |
| Water Solubility | Soluble in dimethyl sulfoxide and dimethyl formamide. Slightly soluble in water. Insoluble in ethanol. |
| λmax | 245nm(H2O/MeOH)(lit.) |
| Merck | 14,4922 |
| Stability | Incompatible with strong oxidizing agents. |
| InChIKey | DOUYETYNHWVLEO-UHFFFAOYSA-N |
| CAS DataBase Reference | 99011-02-6(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301-H315-H319 | |||||||||
| Precautionary statements | P264-P270-P280-P301+P310-P302+P352-P305+P351+P338 | |||||||||
| Hazard Codes | T,Xi | |||||||||
| Risk Statements | 25-36/37/38 | |||||||||
| Safety Statements | 26-45-36/37/39-27 | |||||||||
| RIDADR | UN 2811 6.1/PG 3 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | NJ5903450 | |||||||||
| HazardClass | 6.1 | |||||||||
| PackingGroup | III | |||||||||
| HS Code | 29339900 | |||||||||
| NFPA 704 |
|
Imiquimod price More Price(6)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | PHR2716 | Imiquimod Pharmaceutical Secondary Standard; Certified Reference Material, certified reference material, pharmaceutical secondary standard, pkg of 500?mg | 99011-02-6 | 500MG | ₹20415.95 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | I5159 | Imiquimod ≥98% (HPLC), solid | 99011-02-6 | 200MG | ₹17190.1 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 401020 | Imiquimod - CAS 99011-02-6 - Calbiochem An imidazoquinoline compound that acts as a potent immunomodulator and displays anti-angiogenic, anti-viral and anti-inflammatory properties. | 99011-02-6 | 250MG | ₹17660.01 | 2022-06-14 | Buy |
| TCI Chemicals (India) | I0747 | Imiquimod | 99011-02-6 | 100MG | ₹6900 | 2022-05-26 | Buy |
| TCI Chemicals (India) | I0747 | Imiquimod | 99011-02-6 | 1G | ₹34700 | 2022-05-26 | Buy |
Imiquimod Chemical Properties,Uses,Production
Description
Aldara was launched in the US for the topical treatment of genital warts caused by human papillomavirus (HPV). It can be prepared in a six step approach beginning with the nucleophilic substitution of 4-chloro-3-nitroquinolone with isobutylamine or via a thermal electrocyclic ring closure of 1 - and 2-azahexatriene systems. Aldara has antiviral and antitumor properties, with the former activity arising from the induction of cytokines, in particular, INF-α. Aldara also induces TNF-γ, IL-1α, IL-1β, IL-1ra, IL-6, IL-8, IL-10, GM-CSF, G-CSF and MID-la formation 1-4 hr after stimuli. The exact cells responsible for the response have not been determined, however, it is not activating T lymphocytes, NK cells, B lymphocytes, or dendritic stem cells but monocytes (CD14+, CD36+, HLA-DR+, HLA-DQ±, CD19-, CD16- and CD23-) are partly responsible. The speculation is that Aldara may interact with a kinase modulating the transduction pathway leading to cytokine genes. There is no direct antiviral activity (induction of IFN does not follow true dose response) and it is not mutagenic. The hydroxylated metabolite also induces IFN-α.
Chemical Properties
White to off white crystalline powder
Uses
Imiquimod is a caspase 3 activator which acts as an immunomodulator and displays antiviral and anti-tumor activity. It is a patient-applied cream used for the treatment of genital warts and basal cell carcinoma. It is also used to cure actinic keratosis on the face and scalp. It belongs to a group of drugs called immune response modifiers, which work by activating the immune system to fight abnormal skin growth.
Indications
Imiquimod (Aldara) is a topical immune response modifier approved for the treatment of anogenital warts (condylomata acuminata). The exact mechanism of action is unknown; it has no direct antiviral activity in vitro. It is thought to work in vivo by inducing the production of tumor necrosis factor (TNF α ), interferons (IFN)α and γ , and other cytokines with antiviral activity. It may also be useful for treatment of other types of warts, molluscum contagiosum, and certain forms of skin cancer. Local irritant reactions related to the frequency of application are common.
Pharmaceutical Applications
An imidazoquinoline used for the treatment of genital and perianal warts. While the mechanism of action is not precisely known, it is thought to induce interferon. It has no direct antiviral activity. The 5% cream applied three times a week for up to 16 weeks resulted in total wart clearance in 50% of patients, with a better response in women than in men. Local reactions are common and include erythema, erosion, excoriation and edema.
Biological Activity
Immunomodulator that displays antiviral and antitumor activity. Acts as a Toll-like receptor 7 (TLR-7) agonist; stimulates proinflammatory cytokine production and activates NF- κ B.
Mechanism of action
Imiquimod (Aldara) is an imidazoquinolone amine that is an immune responsemodifier.
Its exact mechanism is unknown in the topical treatment of HPV and molluscum
contagiosum but may be related to the immunomodulating effect of the drug. It is also
effective in the treatment of actinic keratoses and superficial basal cell carcinoma.
It induces production of a variety of cytokines and can enhance cell-mediated
cytolytic antiviral activity. It is a rapid and potent inducer of interferon-α,
interleukin?1 α and β, interleukin 6, interleukin 8, tumor necrosis factor-α,
granulocyte-macrophage colony-stimulating factor, and granulocyte colonystimulating
factor. Systemic absorption is minimal. It is generally well tolerated.
Adverse local reactions include erythema, erosion, excoriation, flaking, and edema
of the treatment sites.
Imiquimod Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| USV Pvt Ltd | +91-2267861111 +91-2225564048 | Maharashtra, India | 36 | 58 | Inquiry |
| Glenmark Pharmaceuticals Limited | +912240189999 | Maharashtra, India | 93 | 58 | Inquiry |
| Aruvi Labs | +91-8056181939 +91-8056181939 | Tamil Nadu, India | 149 | 58 | Inquiry |
| Solara Active Pharma Sciences Ltd | +91-8046632100 +91-7075706520 | Bangalore, India | 65 | 58 | Inquiry |
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| BDR Pharmaceuticals International Pvt Ltd | +91-2240560560 +91-7718884418 | Maharashtra, India | 206 | 58 | Inquiry |
| OCEAN TRADING CORPORATION | +91(22) 24921669 | New Delhi, India | 6211 | 58 | Inquiry |
| WANBURY LTD | +91-2267942222 | New Delhi, India | 16 | 58 | Inquiry |
| GLENMARK LIFE SCIENCES LTD | +91 22 4018 9999 | New Delhi, India | 103 | 58 | Inquiry |
| USV PRIVATE LTD | +91-22-2556-4048 & 6786-1111 | New Delhi, India | 27 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| USV Pvt Ltd | 58 |
| Glenmark Pharmaceuticals Limited | 58 |
| Aruvi Labs | 58 |
| Solara Active Pharma Sciences Ltd | 58 |
| Ralington Pharma | 58 |
| BDR Pharmaceuticals International Pvt Ltd | 58 |
| OCEAN TRADING CORPORATION | 58 |
| WANBURY LTD | 58 |
| GLENMARK LIFE SCIENCES LTD | 58 |
| USV PRIVATE LTD | 58 |
99011-02-6(Imiquimod)Related Search:
1of4
chevron_right